Please join Bill Carpou, CEO, Octane and Bobby Azamian, CEO, Tarsus Pharmaceuticals, Inc as they discuss how Tarsus has raised capital and completed an IPO.

About Tarsus:
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions where there are limited treatment alternatives. We are advancing our pipeline to address a number of diseases across therapeutic categories including eye care, dermatology, and other diseases with high unmet needs.

Register Here